Peringatan Keamanan

The oral LD50 for flavoxate HCl in rats is 4273 mg/kg. The oral LD50 for flavoxate HCl in mice is 1837 mg/kg. Symptoms of overdose include convulsions, decreased ability to sweat, (warm, red skin, dry mouth, and increased body temperature), hallucinations, increased heart rate and blood pressure, and mental confusion.

Flavoxate

DB01148

small molecule approved

Deskripsi

A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. PubChem

Struktur Molekul 2D

Berat 391.4596
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Well absorbed from gastrointestinal tract.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

57% of the flavoxate HCl was excreted in the urine within 24 hours.

Interaksi Makanan

1 Data
  • 1. Take with or without food. The absorption is unaffected by food.

Interaksi Obat

1146 Data
Aclidinium The risk or severity of adverse effects can be increased when Flavoxate is combined with Aclidinium.
Mianserin Mianserin may increase the anticholinergic activities of Flavoxate.
Mirabegron The risk or severity of urinary retention can be increased when Flavoxate is combined with Mirabegron.
Potassium chloride The risk or severity of gastrointestinal ulceration can be increased when Flavoxate is combined with Potassium chloride.
Pramlintide The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Flavoxate.
Secretin porcine The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Flavoxate.
Tiotropium The risk or severity of adverse effects can be increased when Flavoxate is combined with Tiotropium.
Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Flavoxate is combined with Topiramate.
Umeclidinium The risk or severity of adverse effects can be increased when Flavoxate is combined with Umeclidinium.
Glycopyrronium The risk or severity of adverse effects can be increased when Flavoxate is combined with Glycopyrronium.
Botulinum toxin type A The risk or severity of adverse effects can be increased when Flavoxate is combined with Botulinum toxin type A.
Glucagon Flavoxate may increase the gastrointestinal motility reducing activities of Glucagon.
Sulpiride Flavoxate may increase the anticholinergic activities of Sulpiride.
Botulinum toxin type B The risk or severity of adverse effects can be increased when Flavoxate is combined with Botulinum toxin type B.
Eluxadoline The risk or severity of constipation can be increased when Flavoxate is combined with Eluxadoline.
Ramosetron The risk or severity of constipation can be increased when Flavoxate is combined with Ramosetron.
Naltrexone The risk or severity of adverse effects can be increased when Flavoxate is combined with Naltrexone.
Bezitramide The risk or severity of adverse effects can be increased when Flavoxate is combined with Bezitramide.
Tramadol The risk or severity of adverse effects can be increased when Flavoxate is combined with Tramadol.
Morphine The risk or severity of adverse effects can be increased when Flavoxate is combined with Morphine.
Hydromorphone The risk or severity of adverse effects can be increased when Flavoxate is combined with Hydromorphone.
Methadone The risk or severity of adverse effects can be increased when Flavoxate is combined with Methadone.
Oxycodone The risk or severity of adverse effects can be increased when Flavoxate is combined with Oxycodone.
Butorphanol The risk or severity of adverse effects can be increased when Flavoxate is combined with Butorphanol.
Dextropropoxyphene The risk or severity of adverse effects can be increased when Flavoxate is combined with Dextropropoxyphene.
Pentazocine The risk or severity of adverse effects can be increased when Flavoxate is combined with Pentazocine.
Sufentanil The risk or severity of adverse effects can be increased when Flavoxate is combined with Sufentanil.
Alfentanil The risk or severity of adverse effects can be increased when Flavoxate is combined with Alfentanil.
Nalbuphine The risk or severity of adverse effects can be increased when Flavoxate is combined with Nalbuphine.
Levorphanol The risk or severity of adverse effects can be increased when Flavoxate is combined with Levorphanol.
Remifentanil The risk or severity of adverse effects can be increased when Flavoxate is combined with Remifentanil.
Buprenorphine The risk or severity of adverse effects can be increased when Flavoxate is combined with Buprenorphine.
Hydrocodone The risk or severity of adverse effects can be increased when Flavoxate is combined with Hydrocodone.
Diphenoxylate The risk or severity of adverse effects can be increased when Flavoxate is combined with Diphenoxylate.
Oxymorphone The risk or severity of adverse effects can be increased when Flavoxate is combined with Oxymorphone.
Dezocine The risk or severity of adverse effects can be increased when Flavoxate is combined with Dezocine.
Levacetylmethadol The risk or severity of adverse effects can be increased when Flavoxate is combined with Levacetylmethadol.
Methadyl acetate The risk or severity of adverse effects can be increased when Flavoxate is combined with Methadyl acetate.
Dihydroetorphine The risk or severity of adverse effects can be increased when Flavoxate is combined with Dihydroetorphine.
Diamorphine The risk or severity of adverse effects can be increased when Flavoxate is combined with Diamorphine.
Ethylmorphine The risk or severity of adverse effects can be increased when Flavoxate is combined with Ethylmorphine.
Etorphine The risk or severity of adverse effects can be increased when Flavoxate is combined with Etorphine.
Dextromoramide The risk or severity of adverse effects can be increased when Flavoxate is combined with Dextromoramide.
Desomorphine The risk or severity of adverse effects can be increased when Flavoxate is combined with Desomorphine.
Carfentanil The risk or severity of adverse effects can be increased when Flavoxate is combined with Carfentanil.
Dihydrocodeine The risk or severity of adverse effects can be increased when Flavoxate is combined with Dihydrocodeine.
Alphacetylmethadol The risk or severity of adverse effects can be increased when Flavoxate is combined with Alphacetylmethadol.
Dihydromorphine The risk or severity of adverse effects can be increased when Flavoxate is combined with Dihydromorphine.
Tapentadol The risk or severity of urinary retention and constipation can be increased when Flavoxate is combined with Tapentadol.
Ketobemidone The risk or severity of adverse effects can be increased when Flavoxate is combined with Ketobemidone.
DPDPE The risk or severity of adverse effects can be increased when Flavoxate is combined with DPDPE.
Lofentanil The risk or severity of adverse effects can be increased when Flavoxate is combined with Lofentanil.
Opium The risk or severity of adverse effects can be increased when Flavoxate is combined with Opium.
Normethadone The risk or severity of adverse effects can be increased when Flavoxate is combined with Normethadone.
Piritramide The risk or severity of adverse effects can be increased when Flavoxate is combined with Piritramide.
Alphaprodine The risk or severity of adverse effects can be increased when Flavoxate is combined with Alphaprodine.
Nicomorphine The risk or severity of adverse effects can be increased when Flavoxate is combined with Nicomorphine.
Meptazinol The risk or severity of adverse effects can be increased when Flavoxate is combined with Meptazinol.
Phenoperidine The risk or severity of adverse effects can be increased when Flavoxate is combined with Phenoperidine.
Phenazocine The risk or severity of adverse effects can be increased when Flavoxate is combined with Phenazocine.
Tilidine The risk or severity of adverse effects can be increased when Flavoxate is combined with Tilidine.
Carfentanil, C-11 The risk or severity of adverse effects can be increased when Flavoxate is combined with Carfentanil, C-11.
Codeine The risk or severity of adverse effects can be increased when Flavoxate is combined with Codeine.
Meperidine The risk or severity of adverse effects can be increased when Flavoxate is combined with Meperidine.
Fentanyl The risk or severity of adverse effects can be increased when Flavoxate is combined with Fentanyl.
Benzhydrocodone The risk or severity of adverse effects can be increased when Flavoxate is combined with Benzhydrocodone.
Naloxegol The risk or severity of adverse effects can be increased when Flavoxate is combined with Naloxegol.
Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Flavoxate.
Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Flavoxate.
Metixene The risk or severity of adverse effects can be increased when Metixene is combined with Flavoxate.
Terfenadine The risk or severity of adverse effects can be increased when Terfenadine is combined with Flavoxate.
Buclizine The risk or severity of adverse effects can be increased when Buclizine is combined with Flavoxate.
Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Flavoxate.
Oxyphencyclimine The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Flavoxate.
Procyclidine The risk or severity of adverse effects can be increased when Procyclidine is combined with Flavoxate.
Hyoscyamine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Flavoxate.
Methscopolamine bromide The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Flavoxate.
Darifenacin The risk or severity of adverse effects can be increased when Darifenacin is combined with Flavoxate.
Tridihexethyl The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Flavoxate.
Anisotropine methylbromide The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Flavoxate.
Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Flavoxate.
Nicardipine The risk or severity of adverse effects can be increased when Nicardipine is combined with Flavoxate.
Pirenzepine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Flavoxate.
Homatropine methylbromide The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Flavoxate.
Benzquinamide The risk or severity of adverse effects can be increased when Benzquinamide is combined with Flavoxate.
Tropicamide The risk or severity of adverse effects can be increased when Tropicamide is combined with Flavoxate.
Cocaine The risk or severity of adverse effects can be increased when Cocaine is combined with Flavoxate.
Methantheline The risk or severity of adverse effects can be increased when Methantheline is combined with Flavoxate.
Cycrimine The risk or severity of adverse effects can be increased when Cycrimine is combined with Flavoxate.
Cyclopentolate The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Flavoxate.
Oxybutynin The risk or severity of adverse effects can be increased when Oxybutynin is combined with Flavoxate.
Pentolinium The risk or severity of adverse effects can be increased when Pentolinium is combined with Flavoxate.
Trimethaphan The risk or severity of adverse effects can be increased when Trimethaphan is combined with Flavoxate.
Diphenidol The risk or severity of adverse effects can be increased when Flavoxate is combined with Diphenidol.
Fenoterol The risk or severity of adverse effects can be increased when Flavoxate is combined with Fenoterol.
Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione The risk or severity of adverse effects can be increased when Flavoxate is combined with Dihydro-2-thioxo-5-((5-(2-(trifluoromethyl)phenyl)-2-furanyl)methyl)-4,6(1H,5H)-pyrimidinedione.
Solifenacin The risk or severity of adverse effects can be increased when Flavoxate is combined with Solifenacin.
Isopropamide The risk or severity of adverse effects can be increased when Flavoxate is combined with Isopropamide.
Mepenzolate The risk or severity of adverse effects can be increased when Flavoxate is combined with Mepenzolate.
Hexocyclium The risk or severity of adverse effects can be increased when Flavoxate is combined with Hexocyclium.

Target Protein

Muscarinic acetylcholine receptor M1 CHRM1
Muscarinic acetylcholine receptor M5 CHRM5
Muscarinic acetylcholine receptor M2 CHRM2

Referensi & Sumber

Synthesis reference: Da Re, P.; U.S. Patent 2,921,070; January 12, 1960; assigned to Recordati-Laboratorio Farmacologico SPA, Italy.

Contoh Produk & Brand

Produk: 15 • International brands: 7
Produk
  • Apo-flavoxate
    Tablet • 200 mg • Oral • Canada • Generic • Approved
  • Flavoxate
    Tablet • 200 mg • Oral • Canada • Approved
  • Flavoxate Hydrochloride
    Tablet, film coated • 100 mg/1 • Oral • US • Generic • Approved
  • Flavoxate Hydrochloride
    Tablet, film coated • 100 mg/1 • Oral • US • Generic • Approved
  • Flavoxate Hydrochloride
    Tablet, film coated • 100 mg/1 • Oral • US • Generic • Approved
  • Flavoxate Hydrochloride
    Tablet • 100 mg/1 • Oral • US • Generic • Approved
  • Flavoxate Hydrochloride
    Tablet, film coated • 100 mg/1 • Oral • US • Generic • Approved
  • Flavoxate Hydrochloride
    Tablet • 100 mg/1 • Oral • US • Generic • Approved
Menampilkan 8 dari 15 produk.
International Brands
  • Bladuril — Sanofi
  • Flavosert — Daito
  • Progut — Sanwa Kagaku
  • Sawadaron — Sawai Seiyaku
  • Uridron — Johnson
  • Uripax — Farmindustria
  • Uroxal — Sandoz

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul